RAD Radiopharm Theranostics Limited
—Mkt Cap: —P/E: —1d ago
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the Uni…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value10.49M USD
Revenue (TTM)8.89M USD
Gross Profit27.14K USD
Net Income (TTM)-26.50M USD
Revenue/Share0.0040 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees14
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU0000181851
Valuation
P/E (Trailing)—
P/E (Forward)-0.34
PEG—
EV/EBITDA-0.30
EV/Revenue1.18
P/S1.70
P/B0.71
EPS (TTM)-0.02
EPS (Forward)-0.01
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin1.08%
Oper. Margin-400.35%
EBITDA Margin0.00%
Profit Margin-1055.27%
ROE-85.60%
ROA-44.34%
Growth
Revenue Growth-36.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.48M USD
CapEx (TTM)—
FCF Margin-242.07%
FCF Yield—
Net Debt-2.86M USD
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity—
Current Ratio1.16
Quick Ratio1.14
Book Value/Sh0.0070 AUD
Cash/Share0.0010 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.1488 AUD
Target Range0.1488 AUD – 0.1488 AUD
# Analysts1
Ownership
Shares Out.4.38B
Float3.59B
Insiders21.40%
Institutions8.47%
Technical
SMA 500.0086 AUD
SMA 2000.0175 AUD
Beta0.86
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)6.51M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—